{"transactions":[{"id":3529164,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":157657,"kind":"organization","name":"Richard King Mellon Foundation","position":1,"cik":"0001774767","reported_name":"Richard King Mellon Foundation","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-05-13T21:00:58.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":1908450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":222816},"source":{"system":"sec-edgar","filing":"0000899243-19-013252","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013252/doc4.xml","form_type":"4"}},{"id":3529163,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":157657,"kind":"organization","name":"Richard King Mellon Foundation","position":1,"cik":"0001774767","reported_name":"Richard King Mellon Foundation","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:00:58.000Z","date":"2019-05-09","kind":"purchase","acquired":true,"shares":100000,"price":10,"value":1000000.0,"ownership":{"direct":true},"balance_after":347157,"source":{"system":"sec-edgar","filing":"0000899243-19-013252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013252/doc4.xml","form_type":"4"}},{"id":3529162,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":157657,"kind":"organization","name":"Richard King Mellon Foundation","position":1,"cik":"0001774767","reported_name":"Richard King Mellon Foundation","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:00:58.000Z","date":"2019-05-09","kind":"other","acquired":true,"shares":24341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Consists of shares transferred to Richard King Mellon Foundation by TPG Biotechnology Partners III, L.P. in connection with the closing of the Issuer's initial public offering."}],"balance_after":247157,"source":{"system":"sec-edgar","filing":"0000899243-19-013252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013252/doc4.xml","form_type":"4"}},{"id":3529161,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":157657,"kind":"organization","name":"Richard King Mellon Foundation","position":1,"cik":"0001774767","reported_name":"Richard King Mellon Foundation","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:00:58.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":222816,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":222816,"source":{"system":"sec-edgar","filing":"0000899243-19-013252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013252/doc4.xml","form_type":"4"}}]}